API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RespireRx intends to use the net proceeds to fund phase 2 clinical study of CX1739, its Lead AMPAkine, to improve bladder function in patients with spinal cord injury.
Lead Product(s): Ampakine
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: CX1739
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Department of Defense
Deal Size: $1.8 million Upfront Cash: Undisclosed
Deal Type: Funding May 29, 2024
Details:
The collaboration aims to to study the possibility of using CX1739, RespireRx’s lead clinical AMPAkine, for the treatment of a major class of GRIA disorders.
Lead Product(s): Ampakine
Therapeutic Area: Rare Diseases and Disorders Product Name: CX1739
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University College London
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2023